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Background: Antihypertensive agents can reduce arterial stiffness. We hypothesized that an 
angiotensin receptor blocker (ARB) irbesartan and an angiotensin converting enzyme inhibitor 
(ACEI) lisinopril improved arterial compliance.
Methods: A randomized, double-blind, double-dummy, controlled crossover trial. Fifteen hyper-
tensive patients, mean age 65.5 ± 8.9 years (mean ± SD) were given irbesartan (150 to 300 mg/day) 
or lisinopril (10 to 20 mg/day) for 12 weeks and then crossed over for 12 weeks. Pulse wave 
velocity (PWV) in the carotid-femoral (CF), carotid-radial (CR), and femoral dorsalis-pedis 
(FD) were measured using a Complior® PWV system.
Results: After 12 weeks, systolic blood pressure (SBP) decreased from 162.4 ± 12.9 to 
134.5 ± 14.8 with irbesartan and to 145.2 ± 25 mmHg with lisinopril. Irbesartan and lisinopril 
reduced PWV (CF) in the elastic arterial system from 15.1 ± 5 to 13.3 ± 2.6 (p  0.005) and 
to 14 ± 4.7 (p  0.05) m/s respectively (p = 0.345). Irbesartan reduced PWV (CR) and PWV 
(FD), whereas lisinopril did not. The difference between treatments was significant after SBP 
adjustment (p = 0.037 for PWV (CR) and p  0.001 for PWV (FD)).
Conclusions: Irbesartan improved arterial compliance in elastic and muscular arteries, whereas 
lisinopril improved it only in elastic arteries.
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Introduction
Hypertension is one of the most important risk factors for cardiovascular diseases 
and is associated with increased morbidity and mortality.1 It is known that the 
treatment of hypertensive subjects reduces the diseases associated with hypertension, 
for example stroke and coronary artery disease.2,3 Despite this favorable effect of 
antihypertensive treatment, the incidence of cardiovascular diseases remains higher 
in treated hypertensives than in matched controls with similar blood pressure (BP) 
levels,4 suggesting the presence of other additional risk factors, such as previous 
vascular damage, which may be represented by a decreased arterial compliance. 
Increased arterial stiffness in particular as assessed by pulse wave velocity (PWV), is 
an independent marker of cardiovascular disease in hypertensive subjects and is linked 
to ventricular hypertrophy and atherosclerosis.5–9 It is also higher in patients with end 
stage renal disease and diabetes.10–12 Changes in arterial compliance have been used 
to assess the effect of some therapies.13,14
Angiotensin II plays an important role in development of an increased BP and also 
tissue damage. The two categories of drugs acting on the renin-angiotensin system 
have been shown to have beneficial effects on BP, heart and arteries. The inhibition Vascular Health and Risk Management 2009:5 588
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of angiotensin-converting enzyme (ACE) can provide a 
protective effect on the adverse changes due to hypertension 
and prevent cardiovascular outcomes, possibly more than 
is achieved with diuretic based-therapy.15 Treatment with 
ACE inhibitors increases arterial distensibility16 and drugs 
blocking the angiotensin II receptor have been shown 
to improve endothelial function and increase arterial 
compliance of small and large arteries in addition to their 
antihypertensive effect.17–19 It has been suggested that both 
valsartan and captopril reduce the pulse wave velocity (PWV) 
and Augmentation Index by a similar amount in essential 
hypertension.20
The purpose of this study was to assess the effect of 
an angiotensin receptor blocker (ARB), irbesartan, and an 
ACE inhibitor (ACEI), lisinopril, on arterial compliance, 
comparing the effects of these two antihypertensive drugs 
on different arterial segments, one predominately elastic and 
the other predominately muscular.
Methods
study population
We performed a randomized, double-blind, double-dummy, 
controlled crossover trial. Fifteen hypertensive patients 
without  cardiovascular  complications,  mean  age 
65.5 ± 8.9 years (mean ± SD) were recruited. They were 
all nonsmokers. They were randomly allocated to 
receive irbesartan (150 to 300 mg/day) or lisinopril 
(10 to 20 mg/day) for 12 weeks and then immediately 
crossed over for a further 12 weeks.
The study was approved by the Ethics Committee of the 
Hammersmith Hospital Trust, London UK.
exclusion criteria
We excluded subjects on hormone replacement therapy or 
with a history of cardiac failure or valvular heart disease. 
Subjects with contraindications to an ACEI or ARB were 
also excluded.
study design
Patients who were currently taking antihypertensive 
medication had this stopped for 2 weeks prior to the screening 
visit, while having their BP monitored regularly. Between 
the screening and baseline visit, BP was measured once a 
week for 3 weeks. On these occasions the mean of three 
measurements was recorded and used for fulfilling the study 
entry criteria, ie, sitting systolic BP (SBP) 160 mmHg 
and/or sitting diastolic BP (DBP)  90 mmHg.
At the screening visit written informed consent was 
obtained and medical history recorded. Lying, sitting and 
standing BP were measured and a physical examination 
performed. PWV and BP were recorded at the baseline visit 
and were repeated at 12 and 24 weeks.
The initial treatment was 150 mg irbesartan or 10 mg 
lisinopril. These were titrated to 300 mg and 20 mg respectively 
at weeks 6 and 18 if the SBP  160 mmHg and/or the DBP 
was  90 mmHg. At week 12, the patients were crossed over 
and received the other drug.
statistical analysis
The baseline data are presented as means ± standard 
deviation. Data were analyzed according to the method for 
crossover trials described by Senn21 using SAS Version 8. 
Parametric data were analyzed by means of a matched 
paired t-test with adjustment for any period effect and a 
test for carry-over. PWV readings were converted for a 
standardized reading of 150 mmHg and repeat t-test was 
performed between the two groups to eliminate any effect 
of BP on PWV.
Procedures
Baseline characteristics were measured (Table 1).
Blood pressure (BP)
The average of three BP readings at the brachial artery, 
taken at 5-minute intervals, in the right upper arm of the 
supine subject, was performed using an Omron HEM-705CP 
automatic BP recording unit.
Table 1 characteristics of the study population at baseline
Mean ± SD Range
Age (years) 65.1 ± 9.5 53–80
systolic blood pressure (mmHg) 162.4 ± 12.9 135–178
Diastolic blood pressure (mmHg) 98.7 ± 8.1 82–110
PWV carotid-femoral (m/s) 15.1 ± 5.0 9.3–29.3
PWV carotid-radial (m/s) 12.4 ± 2.3 9.4–16.8
PWV femoral-dorsalis pedis (m/s) 11.0 ± 2.6 7.3–17.2
Triglycerides (mmol/L) 1.9 ± 0.98 1.0–5.0
cholesterol (mmol/L) 6.2 ± 1.47 3.6–9.2
LDL cholesterol (mmol/L) 4.1 ± 1.44 1.2–6.6
HDL cholesterol (mmol/L) 1.28 ± 0.68 0.5–3.5
Height (cm) 166.3 ± 9.4 152–181
Weight (kg) 77.8 ± 15.7 47–96
BMi (kg/m2) 28.4 ± 5.2 20.4–38.4
Abbreviations: BMi, body mass index; PWV, pulse wave velocity; LDL cholesterol, 
low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol.Vascular Health and Risk Management 2009:5 589
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Pulse wave velocity (PWV)
PWV in the central, elastic arteries (carotid-femoral region) 
and the peripheral, muscular arteries (carotid-radial and 
femoral-dorsalis pedis regions) were determined using a 
Complior® (Colson Medicals, Paris) PWV recording unit.22 
Two sensors were positioned, one at the base of the right 
common carotid artery and one over the radial artery, similarly 
over the right common carotid artery and the right femoral 
artery and over the right femoral artery and the ipsilateral 
dorsalis pedis artery, thereby continuously measuring pulse 
wave signals. Distances between the two applanation sites 
were measured as a straight line between these points on the 
skin surface, using a tape measure. The time interval between 
the feet of two simultaneously recorded waves at the two 
applanation sites was determined and PWV was calculated.
Results
The characteristics of study population are shown in Table 1. 
We studied 15 patients (7 women and 8 men).
After 12 weeks of treatment SBP decreased from 
162.4 ± 12.9 mmHg to 134.5 ± 14.8 mmHg (p  0.05) with 
irbesartan and to 145.2 ± 25 mmHg (p  0.05) with lisinopril 
and DBP from 98.7 ± 8.1 mmHg to 78.6 ± 9.2 mmHg 
(p  0.05) and to 84.1 ± 11.6 mmHg (p  0.05) with 
lisinopril (Table 2, Figure 1). There was a trend to significant 
differences in the decrease of SBP and DBP between the two 
drugs (p = 0.08).
We found a significant decrease of PWV (C-F) for 
both drugs after 12 weeks of treatment. The PWV (C-F) 
decreased from 15.1 ± 5 m/s to 13.3 ± 2.6 m/s (p  0.005) 
and to 14 ± 4.7 m/s (p  0.05) with irbesartan and lisinopril 
respectively (Table 2). The effects of the two treatments were 
not statistically significantly different (p = 0.345).
We found significant decrease of PWV (F-D) for 
irbesartan, but not for lisinopril. The PWV (F-D) decreased 
after treatment with irbesartan from 11 ± 2.6 m/s to 
10.1 ± 2.6 m/s (p  0.05) (Table 2). This difference between 
the treatments was statistically significant before (p = 0.01) 
and after (p  0.001) adjustment for SBP = 150 mmHg.
PWV (C-R) after 12 weeks of treatment changed from 
12.4 ± 2.3 m/s to 11.6 ± 2.2 m/s (p = 0.19) with irbesartan 
and to 12.4 ± 2.4 m/s (p = 0.99) with lisinopril. After adjust-
ment for SBP = 150 mmHg this value changed respectively 
to 11.0 ± 2.1 m/s (p = 0.02) and to 12.2 ± 2.5 m/s (p = 0.76) 
(Table 2).
PWV (F-D) after 12 weeks of treatment changed from 
11.0 ± 2.6 m/s to 10.1 ± 2.4 m/s (p  0.05) with irbesartan and 
to 11.4 ± 1.5 m/s (p = 0.85) with lisinopril. After adjustment 
for SBP = 150 mmHg this value changed respectively to 
10.9 ± 2.3 m/s (p  0.05) and to 11.7 ± 2.4 m/s (p = 0.86) 
(Table 2).
Discussion
This study investigated the effects of two different 
antihypertensive drugs, lisinopril and irbesartan, on the 
PWV, an index of arterial compliance, in predominantly 
elastic compared with predominantly muscular arteries. 
There was a large BP drop in the patients included in the 
two groups, which may be due to the fact that both medica-
tions were titrated upwards at close intervals although the 
BP readings at the end of the 12 weeks were not significantly 
different statistically between the two. However lisinopril 
Table 2 Baseline and end of trial results
Baseline 12 weeks irbesartan 12 weeks lisinopril p value irbesartan vs 
lisinopril
sBP (mmHg) 162.4 ± 12.9 134.5 ± 14.8* 145.2 ± 25* 0.08
DBP (mmHg) 98.7 ± 8.1 78.6 ± 9.2* 84.1 ± 11.6* 0.08
PWV (cF) (m/sec) 15.1 ± 5 13.3 ± 2.6** 14 ± 4.7* 0.345
PWV (cF) (m/sec) adjusted 
for sBP = 150 mmHg
14.9 ± 4 13.6 ± 3.2** 15.6 ± 4.9* 0.241
PWV (cR) (m/sec) 12.4 ± 2.3 11.6 ± 2.2 12.4 ± 2.4 0.126
PWV (cR) (m/sec) adjusted 
for sBP = 150 mmHg
12.2 ± 1.9 11.8 ± 2.4* 12.6 ± 2.5 0.042
PWV (FD) (m/sec) 11 ± 2.6 10.1 ± 2.4* 11.4 ±1.5 0.01
PWV (FD) (m/sec) adjusted 
for sBP = 150 mmHg
10.7 ± 1.4 10.9 ± 2.3** 11.7 ± 2.4 0.001
*p  0.05, **p  0.01 – Baseline vs 12 weeks treatment
Abbreviations: sBP, systolic blood pressure; DBP, diastolic blood pressure; PWV (cF), pulse wave velocity carotid-femoral; PWV (cR), pulse wave velocity carotid-radial; 
PWV (FD), pulse wave velocity femoral-dorsalis.Vascular Health and Risk Management 2009:5 590
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was not titrated to 40 mg, which could have resulted in the 
differences in the BP lowering effects between the two drugs. 
Recent analysis of the CALM II study showed that lisinopril 
may have different effects on SBP, DBP and pulse pressure 
compared to candesartan (an ARB),23 and since 24-hour 
ambulatory BP monitoring was not performed in this study, 
the observed differences in BP reduction and subsequent 
differences in PWV need a larger study including 24-hour 
BP monitoring. However, given the different resultant BP 
findings at the end of the 12 weeks, and knowing that BP 
reduction affects vascular compliance, the underlying 
biologic effects of the two drugs can not be fully explained. 
A way to address this impact of differences in achieved BP 
readings would be to titrate both drugs upwards to result in 
similar BP readings at the end of the study period.
Hypertension is associated with increased arterial 
stiffness7,8 but it is also known that a reduction in BP is 
associated with an improved arterial compliance.23,24 The 
renin-angiotensin system affects the properties of arteries, 
both predominantly elastic and muscular. Neutel et al 
showed that benazepril improved arterial compliance in 
monotherapy and more efficaciously in combination with 
amlodipine.16 Shargorodsky et al showed the positive effect 
of prolonged treatment with the AT1 receptor blocker 
valsartan on the small and large arterial compliance in a group 
of uncomplicated essential hypertensives.17 Only one other 
study compared the effect of ARBs with ACEIs on arterial 
compliance, showing a significant decrease in augmentation 
index and PWV with both drugs,20 but did not analyze the 
effect of these on different types of arteries.
Our results confirm the finding of these previous studies 
on the PWV, one of the most important measures of arterial 
compliance. Evaluating the PWV, it has been possible 
for us compare the effect of these two drugs on different 
types of arteries. We assessed PWV C-F, PWV C-R and 
PWV F-D to study different segments of the arterial tree. 
Our findings confirm the positive effects of irbesartan 
and lisinopril on improving arterial compliance in elastic 
vessels. After 12 weeks of treatment for both the drugs the 
decrease in PWV C-F was statistically significant. This 
suggests a positive effect of these two drugs in improving 
the cardiovascular risk, over and above the known effects of 
lowering BP that were evident and statistically significant 
in our study.
Similar effects were also seen with irbesartan on the 
muscular arteries. When on treatment with irbesartan but 
not when on lisinopril we found a significant decrease in the 
PWV F-D, suggesting a positive effect of the ARBs on the 
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Figure 1 Blood pressure systolic (SBP) and diastolic (DBP) at baseline and after 12 weeks treatment with irbesartan and lisinopril.   The changes are statistically significant for 
both drugs (p  0.05) for sBP and DBP.Vascular Health and Risk Management 2009:5 591
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arterial compliance of the muscular vessels. Our finding is 
important as it was also significant after adjustment for SBP. 
Correcting for SBP also showed that irbesartan produced a 
similar effect on the muscular arteries in the carotid-radial 
region. This suggests that irbesartan improved arterial com-
pliance in the muscular arteries independently of its effect 
on BP, whereas lisinopril did not.
There are a number of large epidemiological studies 
showing that different antihypertensive agents have differ-
ent outcomes. For example in the LIFE trial it was shown 
that treatment with losartan was more effective than atenolol 
in reducing cardiovascular morbidity and mortality as well 
as mortality from all causes in patients with hypertension, 
diabetes and LVH.25
In elderly patients with heart failure the ELITE-I26 trial 
showed better outcomes with an ARB than with an ACEI, 
showing that treatment with losartan was associated with a 
lower mortality than that with captopril. This effect was not 
sustained in the ELITE-II trial.27
In our study the different effects of the two drugs on 
muscular arteries is difficult to explain. The effects may be 
due to a more specific effect of the ARB on the vascular 
smooth muscle contraction or due to a difference in release 
of some endothelial mediators. However, some studies have 
shown a similar increase in the bioavailability of nitric oxide 
after treatment with both drugs.28 There may be some other 
properties of the ARBs that explain this finding. There is 
some evidence that ARBs improve erectile dysfunction in 
hypertensive men and that that this may not be apparent with 
an ACEI.29 Although there are many possible explanations 
for the difference, it is clear from our study that the short-
term vascular effects are different. It is not clear if they are 
sustained over a longer period and a long-term study needs to 
be carried out. However, it is certain that the effect of these 
two antihypertensive agents on arteries is different, even after 
the adjustment for SBP. This may have an important clinical 
relevance and it may further add to the evidence required to 
choose antihypertensive agents.
There are a number of limitations of this study. The 
sample size was small. However, the changes in PWV from 
the baseline were statistically significant (23.8% of reduction 
in PWV C-F with irbesartan and 10.6% with lisinopril after 
adjustment for SBP of 150 mmHg), despite the small number 
of patients involved, suggesting the importance of the effect 
of these two drugs on arterial compliance. It is important to 
note that PWV is not the only index of arterial compliance 
and other techniques should be used to confirm our results. 
However, PWV is known to be one of the most important 
and commonly used indices of arterial stiffness. A washout 
period between the two drug regimes at the crossover point 
of 12 weeks was not carried out, but this would not have 
influenced the final statistical analysis as the BP readings 
analyzed were adjusted for SBP of 150 mmHg. Arterial 
compliance was not measured after the 12 weeks period of 
the study. In such a small sample size, the power to detect any 
crossover effects may be difficult to establish, and a larger 
study is needed with adjustment for the carry over effects.
In conclusion, both an ARB and an ACEI improved 
arterial compliance in the central elastic arteries. Irbesartan 
improved the vascular compliance also in muscular 
arteries, suggesting an additive action of this class of drugs, 
independently of its effect on BP.
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